2022
DOI: 10.1200/jco.2022.40.16_suppl.e18527
|View full text |Cite
|
Sign up to set email alerts
|

Participatory Action for Access to Clinical Trials (PAACT): Increasing participation of blacks in Southeastern Michigan in cancer clinical trails.

Abstract: e18527 Background: The underrepresentation of minority populations in research violates principles of distributive justice, slows scientific progress, and exacerbates health disparities. Henry Ford Cancer Institute (HFCI) is one of 20 sites offering clinical trials in Michigan and currently participates in 1300 trials. The rate of cancer cases at HFCI is 78% in whites and 21.9% in Blacks/African Americans (B/AA). However, analysis of cancer clinical trials conducted at HFCI showed participation rates to be 2.… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
2
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(2 citation statements)
references
References 0 publications
0
2
0
Order By: Relevance
“…Exclusion has been related to the lack of reporting of outcomes in research studies by race and ethnicity, impacting on the evidence base for clinical decision-making 14. Exclusion is reported to have been observed in commercial cancer trials, where eligibility criteria can be very restrictive 50–52. These trials often exclude individuals with comorbidities, which are more prevalent in black and ethnic minority populations, preventing access to new treatments, such as immunotherapy 51 52.…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…Exclusion has been related to the lack of reporting of outcomes in research studies by race and ethnicity, impacting on the evidence base for clinical decision-making 14. Exclusion is reported to have been observed in commercial cancer trials, where eligibility criteria can be very restrictive 50–52. These trials often exclude individuals with comorbidities, which are more prevalent in black and ethnic minority populations, preventing access to new treatments, such as immunotherapy 51 52.…”
Section: Introductionmentioning
confidence: 99%
“…Exclusion is reported to have been observed in commercial cancer trials, where eligibility criteria can be very restrictive 50–52. These trials often exclude individuals with comorbidities, which are more prevalent in black and ethnic minority populations, preventing access to new treatments, such as immunotherapy 51 52. The impact of eligibility criteria on inclusion requires further investigation to find solutions.…”
Section: Introductionmentioning
confidence: 99%